Steven M. Greenberg, MD, PhD, FAHA, Chair; Wendy C. Ziai, MD, MPH, FAHA, Vice Chair;
Charlotte Cordonnier, MD, PhD; Dar Dowlatshahi, MD, PhD, FAHA; Brandon Francis, MD …

Background and Purpose—This scientific statement provides an overview of the evidence
on vascular contributions to cognitive impairment and dementia. Vascular contributions to …

Acetylcholinesterase is involved in the termination of impulse transmission by rapid
hydrolysis of the neurotransmitter acetylcholine in numerous cholinergic pathways in the …

Dementia is one of the major causes of dependency after stroke. The prevalence of
poststroke dementia (PSD)—defined as any dementia occurring after stroke—is likely to …

Background: The effectiveness of the 5 US Food and Drug Administration–approved
pharmacologic therapies for dementias in achieving clinically relevant improvements is …

Agitation is a behavioral syndrome characterized by increased, often undirected, motor
activity, restlessness, aggressiveness, and emotional distress. According to several …

The aim of this international guideline on dementia was to present a peer‐reviewed
evidence‐based statement for the guidance of practice for clinical neurologists, geriatricians …

Background Cholinesterase inhibitors and memantine do not have regulatory approval in
most of the world for treatment of vascular dementia. A systematic review and meta-analysis …

One of the most widely used guides to prescribing psychiatric medications, the Tenth Edition
of Maudsley Prescribing Guidelines returns with fully updated content and new sections on …

ContextThe prevalence of mixed dementia, defined as the coexistence of Alzheimer disease
(AD) and vascular dementia (VaD), is likely to increase as the population ages. ObjectivesTo …